CD8A and neoplasm: PTT can increase the antigenicity and adjuvanticity of tumor sites by promoting the release of tumor-related antigens and damage-associated molecular patterns and by increasing the expression of major histocompatibility complex class I (MHC-I) molecules on dying tumor cells, which sensitizes CD8+ T cells.